logo

Clinical Trial Calendar

Share SHARE
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Dec 2016
PROTEON THERAPEUTICS INC
Topline data from phase 3 trial of Vonapanitase (PATENCY-1)
To improve arteriovenous fistula patency for hemodialysis in patients with CKD
Dec 2016
INOTEK PHARMACEUTICALS CORP
Topline data from 1st Phase 3 trial of Trabodenoson (MATrX-1)
Primary open-angle glaucoma or ocular hypertension
01-Dec-2016 To 30-Mar-2017
Galmed Pharmaceuticals Ltd.
Interim analysis of phase 2b trial of Aramchol(ARREST)
Nonalcoholic steatohepatitis, or NASH
Dec 2016
ChromaDex Corp.
Results from 2nd human clinical trial of NIAGEN
Increase the mitochondrial co-enzyme NAD+ and NAD+ metabolite concentrations
Dec 2016
Cerecor Inc.
Topline data from phase 2 trial of CERC-501
smoking cessation
15-Nov-2016
The Medicines Co.
Data from of proof of concept study of MDCO-216 (MILANO-PILOT)
atherosclerotic plaque
15-Nov-2016
The Medicines Co.
Data from Phase 2 trial of PCSK9si (ORION 1)
atherosclerotic cardiovascular disease
Nov 2016
Cerecor Inc.
Data from phase 2 study of CERC-301
Major depressive disorder
Nov 2016
SCYNEXIS, Inc.
Results from phase I study of IV SCY-078
Vulvovaginal candidiasis
10-Oct-2016
Peregrine Pharmaceuticals Inc
Top-line data from phase 3 trial of Bavituximab (SUNRISE)
metastatic non-squamous non-small cell lung cancer
Q4 2016
ARADIGM CORP
Topline data from phase 3 study of Pulmaquin (ORBIT-3)
non-cystic fibrosis bronchiectasis
Q4 2016
ARADIGM CORP
Topline data from phase 3 study of Pulmaquin (ORBIT-4)
non-cystic fibrosis bronchiectasis
Q4 2016
MABVAX THERAPEUTICS HOLDINGS, INC.
Early readout from phase I trial of MVT-5873
pancreatic and GI cancers
Q4 2016
MABVAX THERAPEUTICS HOLDINGS, INC.
Early readout from phase I trial of MVT-2163
Pancreatic cancer
Q4 2016
Ocera Therapeutics, Inc.
Complete phase 2b trial of IV formulation of OCR-002 (STOP-HE)
acute hepatic encephalopathy
Q4 2016
NeuroDerm Ltd.
Completion of Bioequivalence trial of ND0701
advanced Parkinson’s disease
Oct 2016
Rigel Pharmaceuticals Inc.
Results from 2nd phase 3 study of Fostamatinib (FIT)
chronic/persistent immune thrombocytopenia (ITP)
Q4 2016
Celyad SA
Results from Phase I trial of NKR-2
Acute Myeloid Leukemia and Multiple Myeloma
Q4 2016
aTyr Pharma Inc.
Data from Stage 1 of its phase 1b/2 trial of Resolaris
early-onset FSHD
Q4 2016
Neos Therapeutics, Inc.
Submit NDA for NT-0201
Treatment of ADHD
Q4 2016
Trillium Therapeutics Inc.
Data from phase I study of TTI-621
relapsed or refractory hematologic malignancies
Q4 2016
Mesoblast Limited
Futility analysis of Phase 3 registration trial of MSC-100-IV
Steroid Refractory Acute Graft Versus Host Disease
Q4 2016
CytRx Corp.
Subsequent analysis of phase 3 trial of Aldoxorubicin
Second-Line Soft Tissue Sarcoma
Q4 2016
Tobira Therapeutics Inc.
Full data from phase 2a study of Cenicriviroc (ORION)
Obese adults with suspected non-alcoholic fatty liver disease.
Q4 2016
Aclaris Therapeutics
Results from phase 3 open-label safety trial of A-101
Seborrheic keratosis